- Claritas (KLY) has added Perenlei Enkhbaatar as an independent member of its board of directors
- Dr. Enkhbaatar is an authority on the biology and pathophysiology of nitric oxide and acute lung injury
- As an expert on pulmonary damage, Dr. Enkhbaatar is ideal to guide COVID-19 therapies based on the company’s R-107 compound
- R-107 releases nitric oxide throughout the body to help it combat infections such as COVID-19
- Claritas Pharmaceuticals is a clinical-stage biopharmaceutical company focused on unmet medical needs
- Claritas (KLY) is trading flat at C$0.045 per share
Claritas (KLY) has added Perenlei Enkhbaatar as an independent member of its board of directors.
Dr. Enkhbaatar is an authority on the biology and pathophysiology of nitric oxide and acute lung injury.
He was trained at the University of Saint Petersburg in Russia and served as Senior Lieutenant Physician in the Mongolian Army.
He went on to receive his Ph.D. at Kumamoto University Graduate School of Medical Sciences in Japan. He then undertook post-doctoral training in the Department of Anesthesiology, University of Texas Medical Branch in Galveston, Texas.
For the past 25 years, Dr. Enkhbaatar has played a leading role in elucidating the mechanisms of disease in acute lung injury and acute respiratory distress syndrome secondary to pneumonia, sepsis, toxic gas inhalation and thermal injury associated with smoke inhalation.
As an authority on pulmonary damage, Dr. Enkhbaatar is ideally positioned to guide COVID-19 therapies based on Claritas’ R-107 compound.
Robert Farrell, Claritas’ President and CEO, commented,
“The addition of Dr. Enkhbaatar to the company’s board enhances and strengthens our focus on nitric oxide pharmaceuticals. We previously announced the addition of Dr. Salvatore Cuzzocrea to our board. Both Dr. Enkhbaatar and Dr. Cuzzocrea are internationally renowned authorities and leaders on the biology and pathophysiology of nitric oxide.
They will help guide the company’s development of R-107, our proprietary nitric oxide-releasing compound that is being developed as a treatment for coronavirus, COVID-19, and other viral infections.”
Nitric oxide is part of the body’s natural defense system against viral infections. However, a viral infection can spread more rapidly than the body can produce nitric oxide to combat it.
Claritas is developing R-107 to supplement the body’s natural production of nitric oxide. Following administration orally, nasally or by injection, R-107 releases nitric oxide systemically throughout the body.
Unlike vaccines that may lose effectiveness as the virus mutates, R-107 is expected to be a universal therapy against all COVID-19 strains, including those that are vaccine-resistant.
Claritas Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.
Claritas (KLY) is trading flat at C$0.045 per share as of 11:12 am ET.